Introduction
============

Information on disease prevalence is important for assessing the health needs of populations.[@cky270-B1] Several sources can deliver population disease prevalence estimates, such as surveys,[@cky270-B2] dedicated epidemiologic studies using diagnostics[@cky270-B5] or administrative data sources.[@cky270-B8] Drug use data, especially on prescription drugs, has also frequently been used to estimate disease prevalence.[@cky270-B13]^,^[@cky270-B14] In many countries insurers or providers maintain extensive prescription databases, allowing easy access to national drug use data.

Drug use has several advantages over other sources. Surveys are costly to execute on a large scale. Hospital discharge registers are large, but involve hospital-related events only. In addition, in the Netherlands, the GP-serves as a gatekeeper, implying that patients---except in emergencies---can only visit a medical specialist with a referral of the GP. This means that the GP sees both patients that see only the GP and those he refers to specialist care. Hospital data is therefore more likely that GP data to underestimates the prevalence.[@cky270-B15]^,^[@cky270-B16] GP-registers containing diagnosis codes are not readily available in all countries. Furthermore, GPs may have different coding habits, hindering comparisons between GPs.[@cky270-B17]

While drug use data is often recorded without a diagnosis, some studies base disease prevalence estimates on direct links of specific drug use to the presence of certain diseases.[@cky270-B9]^,^[@cky270-B13]^,^[@cky270-B14]^,^[@cky270-B18]^,^[@cky270-B19] The links are based on literature or medical guidelines. For two reasons, this procedure is problematic. First, many drugs are used for the treatment of multiple diseases; assuming that all patients who take a specific drug do have a specific disease will then lead to overestimation. Second, some patients with a disease are not prescribed the specific drug, and this will lead to underestimation of prevalence.

To overcome these two problems, it is better to estimate the probability of having a specific disease given all different medications a person uses. Avoiding any *a priori* assumption on the relationship between the drugs and diagnoses, machine learning algorithms can be used to estimate this relation from data. In this paper more specifically the Random Forest (RF) algorithm will be applied, as this method yielded the best results in comparison with others.[@cky270-B20]^,^[@cky270-B21]

This algorithm requires a test set with both diagnosis data and drug use. This diagnosis data could also be used directly to estimate disease prevalence. This is the case particularly when it is possible to assume that the set containing diagnosis data is representative for the population of interest. However, using the diagnosis data in combination with drug use as proposed alters the assumption. Rather than that the diagnosis data should be representative for the population of interest, the relationship between diagnosis and drug use should be similar as in the population of interest. This might be a more reasonable assumption in many cases, as medical professionals are influenced by standardized prescription guidelines. Countries which do have a prescription registration, but lack population surveys on disease prevalence, as is often the case, can use the relation derived in comparable countries to obtain prevalence estimates.

Existing applications of RF analysis to the problem of disease prevalence estimates have some limitations. Chaudhry[@cky270-B20] used RF to predict the population prevalence of diabetes and dementia from administrative data in GP and hospital records. However, his choice of predictors was informed by *a priori* knowledge. Khalilia et al.[@cky270-B21] predicted the presence of eight diseases with RF from hospital in-patient data, but did not make any population prevalence estimates.

In contrast, we apply the RF approach to a broad range of 29 diseases. The RF algorithm allows us to select important predictors from the full range of possible drug use predictors. Afterwards, we have a list of predictors for comparison with existing theory based lists of predictors, e.g. the Dutch Pharmacotherapeutic compass.[@cky270-B22]

The objective of this paper hence is to examine for which diseases the prevalence can be estimated using the RF algorithm, and if so, to see which drug groups should be used.

Methods
=======

Random Forest
-------------

Estimating the probability that an individual has a certain disease could be considered a mathematical classification problem. RF is a non-parametric method to address classification problems.[@cky270-B23] For implementation the R-package 'Random Forest'[@cky270-B24] was used.

Data
----

Drug use data of the entire Dutch population is available from the National Health Care Institute (ZiN).[@cky270-B25] The ZiN claims database covers all outpatient prescriptions reimbursed under the Dutch mandatory Health Insurance scheme. Drugs were classified in 204 pharmaceutical groups according to the four position ATC-code. To these groups, age and gender were added as predictors. The dataset contained 47 million individual prescription records in 2010, covering a population of 16.7 million, of which 70% had at least one prescription.

A training set with disease information was obtained from the primary care database of the Netherlands Institute for Health Services Research (NIVEL).[@cky270-B26] As every citizen is required to have a GP---with the exception of those living institutionalized---this means the dataset is likely to cover the whole Dutch population, with the exception of the 80+ population of which in 2010 a significant part lived institutionalized.[@cky270-B27] All patient contacts were labelled with a diagnostic code, ICPC.[@cky270-B28] A person was defined to have a disease when he/she had at least one contact with a GP for this disease over a period of 3 years. All GP-patients with full data available over 2008--2010 were selected. This resulted in a training set of 276 723 individuals. The selection of 29 diseases was based on a list provided by O'Halloran et al.[@cky270-B29] See [Supplementary](#sup1){ref-type="supplementary-material"} file S1 for details. We combined the available data (drug utilization, age and gender, and ICPC codes) at Statistics Netherlands within the System of Social Statistical Datasets (SSD). The SSD allows data from different administrative registers to be combined using an anonymous patient identifier for research purposes.[@cky270-B30]^,^[@cky270-B31]

Implementation of RF
--------------------

Usually, all observations in a training set and all predictors are combined in one RF-analysis. However, within the SSD system, computing power is limited, and analysis with our dataset (276 723 records with 206 variables) proved to be difficult. We therefore used a two-step approach. First, for each chronic disease, persons with the disease were randomly selected, up to a maximum of 5000 patients. To this set, an equal number of persons without the disease was randomly selected and added. For each of these smaller sets, the RF algorithm was applied. The variable importance measure,[@cky270-B24] defined as the average decrease in accuracy when a predictor is left out of the analysis, was evaluated. For each disease, the 10 drug groups with the highest variable importance were selected. By selecting 10 drug groups, the most important predictors were included for all diseases, while limiting the computing times. Second, a new dataset was created for each disease based on the full training set, but only age, gender and the drug groups selected in the first step were added as predictors (276 723 records with 12 variables for each disease), and we applied RF a second time. For each disease this second RF-model was then applied to obtain the probability of having this disease for each individual in the prescriptions database, hence for the 11.6 million Dutch inhabitants that were reimbursed a prescription drug in 2010. The model was also applied to the remaining 5. million Dutch individuals without any prescription. They received for each of the 29 diseases a probability equivalent to the age and gender specific probability in the training set for those diagnosed with the disease, but not receiving any prescription.

Outcome measures
----------------

For each disease, the most important drugs according to the variable importance were compared with theoretical drug classifications included in relevant guidelines. For 13 of the 29 chronic diseases pharmaceutical groups used in the Dutch insurance system were available.[@cky270-B32] In addition, for four other diseases the drugs found were compared with Dutch treatment guidelines: tuberculosis,[@cky270-B33] MS,[@cky270-B34] chronic back or neck disorder[@cky270-B35]^,^[@cky270-B36] and gastric or duodenal ulcer.[@cky270-B37]

To measure the performance of the final RF-models, the area under the Receiver-Operator Curve (AUC) was measured for the training set for each disease separately. An AUC-value above .7 is generally considered useful.[@cky270-B38] To prevent overfitting, 10-fold cross validation was applied.

The AUC and a 95% confidence interval around the AUC-value were obtained using the R-package 'cvAUC'.[@cky270-B39] If the lower boundary of this interval was above .5, we considered the model to perform better than a random prediction.

The predicted population prevalence by age and gender for the Netherlands was graphically compared with a prevalence estimate based on direct extrapolation of the training set prevalence. Correlations were computed as well for the six diseases with lower confidence bound (95%) of the AUC \>.70. The age range considered was 30--80 years, since the prevalence below 30 is very low for most chronic diseases and the 80+ population was not well covered in our training set.

For a binary classification of each individual, a cut-off needs to be chosen. This was done by setting an age and disease-specific cut-off value. All persons with a probability higher than the cut-off were classified as 'ill'. The cut-off was chosen to minimize the deviation between the observed and the predicted prevalence in the training set for each age, gender and disorder.

Results
=======

[Table 1](#cky270-T1){ref-type="table"} gives descriptives for the training set. The average annual number of different pharmaceutical drugs taken by patients in the training set was 2.9, which is very comparable with the utilization in the total Dutch population in the same year (2.8). [Table 1](#cky270-T1){ref-type="table"} also shows that the number of ATC groups utilized by an individual patient rises proportionally with the number of chronic diseases present.

###### 

Pharmaceutical utilization in dataset

                                                         Persons with at least one recorded episode for each chronic disease in 2008--2010   Total number of pharmaceutical groups utilized in 2010   Average number of pharmaceutical groups utilized per person
  ----------------------------------------------------- ----------------------------------------------------------------------------------- -------------------------------------------------------- -------------------------------------------------------------
  Persons without disease                                                                     184 826                                                               328 385                                                      *1.8*
  Persons with 1 chronic disease                                                              60 065                                                                235 032                                                      *3.9*
  Persons with 2 chronic diseases                                                             20 090                                                                125 335                                                      *6.2*
  Persons with 3 chronic diseases                                                              7609                                                                  63 064                                                      *8.2*
  Persons with 4 chronic diseases                                                              2697                                                                  27 190                                                      *9.9*
  Persons with 5 or more chronic diseases                                                      1436                                                                  17 219                                                     *11.6*
  Total                                                                                       276 723                                                               796 225                                                      *2.9*
  Percentage with at least one chronic disease:                                                33.2%                                                                                                 
  Percentage study population with multiple diseases:                                          11.5%                                                                                                 

Legend: Training set population has been divided into six strata, based on the number of chronic diseases present. First column presents stratum. Second column gives population size. Third column gives total number of pharmaceutical groups utilized. Pharmaceutical groups have been defined in terms of an ATC 4 position code: A01A, A02A, etc. Last column gives average utilization in stratum.

[Table 2](#cky270-T2){ref-type="table"} lists the AUC values produced by our analysis, sorted by average AUC. For 17 diseases the lower boundary of the 95% AUC confidence interval was \>.5. For 10 diseases the average AUC was .7 or higher, but for only six the lower boundary of the AUC 95% confidence interval was \>=.7: Parkinson's disease, diabetes mellitus, osteoporosis, heart failure, asthma and chronic obstructive pulmonary disease (COPD).

###### 

Model outcome AUC with confidence interval, ordered by mean AUC

  Disease                                  AUC (95% conf. interval)  Prevalence in training set per 10 000 persons
  --------------------------------------- -------------------------- -----------------------------------------------
  Parkinson's disease                         *.89 (.77--1.00)*      15
  Diabetes mellitus                            *.87 (.85--.90)*      421
  Osteoporosis                                 *.87 (.81--.92)*      103
  Heart failure                                *.81 (.74--.88)*      82
  Chronic obstructive pulmonary disease        *.79 (.75--.83)*      209
  Chronic enteritis/colitis ulcerosa           *.79 (.68--.90)*      31
  HIV/AIDS                                    *.78 (.39--1.00)*      4
  Asthma                                       *.77 (.74--.80)*      424
  Epilepsy                                     *.77 (.66--.87)*      41
  Coronary heart disease                       *.70 (.66--.74)*      255
  Visual disorder                              *.69 (.64--.73)*      191
  Schizophrenia                                *.69 (.48--.89)*      10
  Rheumatoid arthritis                         *.68 (.60--.76)*      66
  Dementia                                     *.67 (.54--.80)*      28
  Congenital neurological anomaly             *.67 (.01--1.00)*      3
  Multiple sclerosis                           *.66 (.42--.90)*      9
  Cancer                                       *.60 (.56--.64)*      264
  Chronic alcohol abuse                        *.59 (.49--.69)*      45
  Depressive disorder                          *.58 (.54--.63)*      253
  Stroke (including TIA)                       *.57 (.52--.63)*      137
  Congenital cardiovascular anomaly            *.57 (.37--.77)*      7
  Chronic back or neck disorder                *.56 (.53--.60)*      432
  Osteoarthritis                               *.56 (.52--.60)*      282
  Anxiety disorder, neurosis, PTSS             *.56 (.50--.61)*      154
  Mental retardation                           *.55 (.36--.74)*      13
  Hearing disorder                             *.52 (.44--.61)*      62
  Anorexia                                     *.52 (.33--.71)*      8
  Gastric or duodenal ulcer                    *.50 (.39--.62)*      25
  Tuberculosis                                 *.50 (.06--.94)*      2

Legend: First column gives name of chronic disease. Second column gives model outcome of RF-analysis as AUC with 95% confidence interval, in order of decreasing AUC. Third column states prevalence of chronic disease or condition in the training set. (*n* = 276 723).

There is some association between the frequency of the disease and the prediction of the AUC. For almost all 12 diseases with a prevalence in the training set higher than 100 per 10 000 persons, the prediction is better than a random assignment. The only exception is anxiety disorder (154 cases per 10 000 persons), with a very poor performance and AUC of .56 (95% cf. = .50--.61). For 11 out of 17 diseases with a frequency below 100 per 10 000 persons, performance is poor, i.e. the lower boundary of the AUC 95% confidence interval was below .5. A notable exception was Parkinson's disease which despite a low frequency (15 per 10 000 persons) seems to be very predictable from drugs utilization.

In [table 3](#cky270-T3){ref-type="table"} predictors of all model output from the RF-analysis are ranked by importance. The shaded areas denote drugs that are also mentioned as indicator drugs for these diseases in the theoretical drug classifications we compared with. Only for cancer we found no similarities. For all other diseases, the ATC codes mentioned by insurers and guidelines are also strong predictors for the corresponding diseases in our RF-models. However, our models show a number of additional predictors for most disorders. [Supplementary](#sup1){ref-type="supplementary-material"} file S2 gives more information.

###### 

Predictors of chronic diseases in Random Forest analysis

  Disease                                                                     ATC4 groups with strongest relation with disease in RF-analysis                                                                                   
  -------------------------------------------------------------------------- ----------------------------------------------------------------- ----------- ----------- ----------- ------ ----------- ----------- ------ ------ ------
  Parkinson\'s disease[^a^](#tblfn4){ref-type="table-fn"}                                                  N04B                                   N04A      Birthyear     L04A      A07E     C10A        C09B      N05A   C03C   N06D
  Diabetes mellitus[^a^](#tblfn4){ref-type="table-fn"}                                                     A10A                                   A10B        C10A        B01A      H04A     C09A        C09B      C08C   C03C   C07A
  Osteoporosis                                                                                             M05B                                   A12A        A11C        L04A      C10A     B01A        C09D      D01A   C09C   D06A
  Heart failure                                                                                            C03C                                   C03D        A12B        C01A      C08D     C08C        C01D      C03A   C10A   C07B
  Chronic obstructive pulmonary disease[^a^](#tblfn4){ref-type="table-fn"}                                 R03A                                   R03B        R06A        A01A      R01A     N06B        J01F      R05D   A06A   J01C
  Chronic enteritis/colitis ulcerosa                                                                       A07E                                   L04A        L01B        B03B      A06A     J01M        A11C      A07D   N02A   M01A
  HIV/AIDS[^a^](#tblfn4){ref-type="table-fn"}                                                              J05A                                   J01E        J04A        J01F      N01B     J07B        D06B      A02B   J01C   J01A
  Asthma^a^                                                                                                R03A                                   R03B        R03C      Birthyear   H02A     A07A        S01G      R01A   R06A   R05D
  Epilepsy[^a^](#tblfn4){ref-type="table-fn"}                                                              N03A                                   N05B      Birthyear     A03F      N05A     B01A        N06A      D04A   D11A   N05C
  Coronary heart disease[^a^](#tblfn4){ref-type="table-fn"}                                                C01D                                   C08D        C03C        C01B      C03A     C09A        D06A      C01E   C09C   B03A
  Visual disorder                                                                                          S01E                                   S01B      Birthyear     S01C      A10B     S01F        D02A      S01A   A10A   S01X
  Schizophrenia^a^                                                                                         N05A                                   N05B        N05C        N04A      N06A     N06B      Birthyear   N03A   A06A   N07C
  Rheumatoid arthritis[^a^](#tblfn4){ref-type="table-fn"}                                                  L04A                                   P01B        A07E        B03B      N02A     L01B        H02A      D02B   M05B   D06A
  Dementia^a^                                                                                              N06D                                 Birthyear     N05A        A12A      C03C     N03A        M05B       Y     D03D   C09D
  Congenital neurological anomaly                                                                          M03B                                   G04B        N03A        J01X      D07X     N05A        J01E      A12A   D01A   N05B
  Multiple sclerosis[^b^](#tblfn5){ref-type="table-fn"}                                                    L03A                                   M03B        G04B        N03A      N06A     N04B        B03B      S01A   J01X   C03C
  Cancer[^a^](#tblfn4){ref-type="table-fn"}                                                              Birthyear                                L02B        H03A          Y       D06A     A04A       Gender     L02A   G03C   A12A
  Chronic alcohol abuse[^a^](#tblfn4){ref-type="table-fn"}                                                 N07B                                   N05A      Birthyear     N05B      G04C     A02B        N06A      M04A   A10B   N05C
  Depressive disorder[^a^](#tblfn4){ref-type="table-fn"}                                                   N06A                                   N05A        N05B        N06B      N05C     N07B        N03A      A03F   A11C   G04B
  Stroke (including TIA)                                                                                   B01A                                   V03A        C01D        C01B      C07A   Birthyear     C08C      C01A   S01C   S01E
  Congenital cardiovascular anomaly                                                                        B01A                                   C07A        J01C        N03A      C09A     D06A        R03B       Y     D02A   S02C
  Chronic back or neck disorder[^b^](#tblfn5){ref-type="table-fn"}                                         N02A                                   M01A        A02B        A06A      N02B     C05A        S02C      N03A   H02A   R05D
  Osteoarthritis                                                                                         Birthyear                                B01A       Gender       M04A      C10A     N02B        C10B      C03A   S01E   N02A
  Anxiety disorder, neurosis, PTSS                                                                         N06A                                   N05B        N05A        C07A      N01B     N05C        A03F      A06A   N03A   D05A
  Mental retardation                                                                                       N05A                                   N03A        D02A        D06A      A06A     N05B          Y       D10A   S01F   N01B
  Hearing disorder                                                                                       Birthyear                                L02A        B02A        S01X      D05A     G04C        H02A      A10B   C08D   C07B
  Anorexia                                                                                                Gender                                  G03A        A06A        A01A       Y       J01X        G03H      R05D   G01A   A12B
  Gastric or duodenal ulcer[^b^](#tblfn5){ref-type="table-fn"}                                             A02B                                   D05A        G04B        A07A      A03A     A03F        M01A      A11C   D06B   A06A
  Tuberculosis[^b^](#tblfn5){ref-type="table-fn"}                                                          J04A                                   D02A        D07X        C01B      J01A     C08C        C03C      S01C   S02C   C03E

Legend: First column gives name of chronic disease. The next 10 columns list the predictors used in the final RF-model, in order of decreasing importance. To facilitate comparison, diseases are presented in the same order as in [table 2](#cky270-T2){ref-type="table"}.

For these diseases, comparison is possible with pharmaceutical groups listed in risk adjustment compulsory insurance. The shaded groups are also used for the detection of these diseases by Dutch insurers.[@cky270-B32]

These diseases have been compared with ATC-groups mentioned in the relevant Dutch treatment guidelines. The shaded groups are included in these guidelines.[@cky270-B33]

The actual prevalence in the training set and the calculated prevalence based on applying the final RF-models have been compared for the six diseases with a lower bound of the AUC 95% confidence interval \>.7. Except Asthma, correlations are above .9. Asthma shows correlations of .43 for males and .66 for females, indicating poor performance. Looking at the graphs for osteoporosis, a large discrepancy exists between predicted and observed prevalence around the age of 70. [Figure 1](#cky270-F1){ref-type="fig"} gives an example (COPD, male). A full set of figures is found in [Supplementary](#sup1){ref-type="supplementary-material"} file S3.

![Example of comparison between Dutch population prevalence for ages 30--80 estimated from model applied to drug utilization data and estimation based on training set for COPD, male](cky270f1){#cky270-F1}

Discussion
==========

For a broad range of 29 diseases, RF was used to predict disease prevalence based on medication use. Predictive performance was acceptable for 6 out of 29 diseases and would result in reliable estimates of population prevalence. Furthermore, we find that theory-based indicator drugs were included in the range of diseases identified by the RF model. This seems to be independent from the performance of the models, which indicates that the RF algorithm can also be used to identify suitable predictors, even in those cases were the predictive performance is low. Especially for diabetes, heart failure and COPD we observe a high correlation between estimated and observed population.

Our outcomes can be compared with a few other studies. Chaudhry[@cky270-B20] predicted the presence of diabetes with an AUC of .95 and dementia with an AUC of .875, higher than the .87 and .67 we found. However, for dementia he used dementia-coded doctor visits as predictors, while we use this as our definition of disease. Khalilia et al.[@cky270-B21] used data on hospital stays as predictors, on a very large set (8 million records). A training set was generated by bootstrapping. The average AUC he reports (.88) is much higher than those we found. For the two diseases which could be directly compared (diabetes and osteoporosis) he finds almost the same AUC (.879 and .870 respectively) as we found, .87 for both. Compared with these two previous studies, we included a relatively broad range of diseases and added the comparison with theory-based models.

While the method seems useful for some diseases, the predictive performance is still low for most diseases. This could have multiple causes. First, for some diseases, there is no standard pattern of drugs included in all treatment options. In addition, drugs might be prescribed for multiple diseases. For instance, the two strongest predictors for asthma and COPD are the same (R03A and R03B, [table 3](#cky270-T3){ref-type="table"}). As a result, misclassification of asthma and COPD patients is likely to occur, which has not been further investigated in this study. Furthermore, patients and GPs may deal with diseases in different ways. Based on patient characteristics a GP will sometimes advise lifestyle changes instead of drugs, but will treat similar cases in other instances immediately with drugs. In addition, the patient may have treatment preferences. The relationship between diagnosis and drugs can also change over time. Innovation or policy changes can strongly influence prescription behaviour, making regular calibration of the algorithms necessary.

Second, the predictive power is likely limited due to weaknesses of the current data. In the current training set, only 3 years of diagnoses are used. While many patients with a chronic disease are visiting a GP more than once every 3 years, some patients who visit less frequently will not occur as diseased in the training set. Furthermore, some diseases might not be treated primarily by a GP, but directly in the hospital, also resulting in missing diagnoses in the training set. As the training set serves as a 'golden standard', any diagnosis errors in the training set will translate into the final predictions. Investing in a smaller set of persons for which disease diagnosis is even more reliable, e.g. through the use of cohort studies may provide a training set with better performance. The disadvantage of such a cohort, and the advantage of our current approach is that for rare diseases, relationships between disease and drugs would have to be derived from only a very limited number of disease cases.

Next to errors in disease diagnosis, drugs use measures could also be improved. Drug use often varies between years. Grouping multiple years of drug use could improve results. Also, more complete drug utilization data could be obtained by including inpatient drugs. For some diseases, utilizing more detailed pharmaceutical predictors, such as ATC4 or ATC5 groups, would improve results.

Even though improvements might be needed to obtain reliable prevalence estimates for most diseases, for 16 out of 17 diseases for which theory-based predictors were found within existing guidelines, important similarities were found. This means that even though the predictive power of the algorithm on the current data is insufficient, it is still possible to identify relevant drug groups. Compared with purely theory-based models, the RF algorithms have the important advantage of coming with confidence intervals and information about model performance. From this similarity we also infer that Dutch general practioners broadly follow existing pharmaceutical guidelines. Cancer was the only disease for which the drugs found using the RF algorithm differ from theory. This could be the result of grouping all cancers together, and many drugs used in cancer treatment were not covered by the dataset as they were prescribed in a hospital setting.

We do not want to suggest that prediction models can entirely replace current GP registers or population surveys. On the contrary, since without these registries the models cannot be built or validated. However, even in countries like the Netherlands which are covered by both population surveys and GP networks the method is of practical value, as it allows for analysis on subgroups, such as regions or stratifications by socio-economic status. The primary care database used as training set has been enlarged in recent years, but still covers at this moment only 10% of the population and the Dutch GPs. Using drug use will allow for better prevalence estimates for the 90% not covered.

Because the full population is covered in the prescription data we use, and the model provides estimates of the probability of having a disease at the individual level, other useful applications would be pre-selecting subjects for medical trials, or making case-mix corrections, e.g. for comparing hospital performance.

To conclude, combining diagnosis data and drug use by the RF algorithm provides can be a useful tool to predict population prevalence. Applications include situations where the diagnosis data is not necessarily representative for the population of interest, but the relation found between diagnosis and drug use is representative. Furthermore, it can be used to select relevant drug use groups in almost all cases.

Supplementary Material
======================

###### 

Click here for additional data file.
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Key pointsDisease prevalences can be estimated from drug use data by Random Forest (RF), a machine learning tool.No prior knowledge about the relationship between drug use data predictors and disease is needed.Survey-based prevalence estimates can easily be elaborated with indepth subgroup analysesRoutine application in public health planning and monitoring is possible.
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